Darinaparsin: A novel organic arsenical with promising anticancer activity

Koren K. Mann, Barbara Wallner, Izidore S. Lossos, Wilson H. Miller

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models. Here, we review the literature describing the signaling pathways and mechanisms of action of darinaparsin and compare them to mechanisms of cell death induced by arsenic trioxide. Darinaparsin has overlapping, but distinct, signaling mechanisms. We also review the current results of clinical trials with darinaparsin (both intravenous and oral formulations) that demonstrate significant antitumor activity.

Original languageEnglish (US)
Pages (from-to)1727-1734
Number of pages8
JournalExpert opinion on investigational drugs
Issue number11
StatePublished - Nov 2009


  • Apoptosis
  • Arsenic
  • Darinaparsin
  • Lymphoma
  • Mitochondria
  • Reactive oxygen species

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Darinaparsin: A novel organic arsenical with promising anticancer activity'. Together they form a unique fingerprint.

Cite this